Sophie Kaspar

Sophie Kaspar

Auto-generated profile, based on publicly available information

Sophie Kaspar

Institute of Human Genetics, University Hospital Cologne, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
SKSophie Kaspar
Sophie Kaspar
COChristian Oertlin
Christian Oertlin
KSKarolina Szczepanowska
Karolina Szczepanowska
AKAlexandra Kukat
Alexandra Kukat
KSKatharina Senft
Katharina Senft
ATAleksandra Trifunovic
Aleksandra Trifunovic
Upon mitochondrial dysfunction, CHOP acts as a rheostat that attenuates prolonged stress and delays the onset of cardiomyopathy.

2 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKarolina Szczepanowska
Karolina Szczepanowska
KSKatharina Senft
Katharina Senft
JHJuliana Heidler
Juliana Heidler
MHMarija Herholz
Marija Herholz
AKAlexandra Kukat
Alexandra Kukat
ATAleksandra Trifunovic
Aleksandra Trifunovic
Regulation of the turnover of complex I (CI), the largest mitochondrial respiratory chain complex, remains enigmatic despite huge advancement in understanding its structure and the assembly. Here, we report that the NADH-oxidizing N-module of CI is turned over at a higher rate and largely independently of the rest of the complex by mitochondrial matrix protease ClpXP, which selectively removes and degrades damaged subunits. The observed mechanism seems to be a safeguard against the accumulation of dysfunctional CI arising from the inactivation of the N-module subunits due to attrition caused by its constant activity under physiological conditions. This CI salvage pathway maintains highly functional CI through a favorable mechanism that demands much lower energetic cost than de novo synthesis and reassembly of the entire CI. Our results also identify ClpXP activity as an unforeseen target for therapeutic interventions in the large group of mitochondrial diseases characterized by the CI instability.

16 June 2016 in Scientific Reports
Verified
Journal Article
Open access
FGFlorian Glenewinkel
Florian Glenewinkel
MCMichael J. Cohen
Michael J. Cohen
CKCason R. King
Cason R. King
SKSophie Kaspar
Sophie Kaspar
SBSimone Bamberg-Lemper
Simone Bamberg-Lemper
WBWalter Becker
Walter Becker
DYRK1A is a constitutively active protein kinase that has a critical role in growth and development which functions by regulating cell proliferation, differentiation and survival. DCAF7 (also termed WDR68 or HAN11) is a cellular binding partner of DYRK1A and also regulates signalling by the protein kinase HIPK2. DCAF7 is an evolutionarily conserved protein with a single WD40 repeat domain and has no catalytic activity. We have defined a DCAF7 binding motif of 12 amino acids in the N-terminal domain of class 1 DYRKs that is functionally conserved in DYRK1 orthologs fromXenopus,Danio rerioand the slime moldDictyostelium discoideum.A similar sequence was essential for DCAF7 binding to HIPK2, whereas the closely related HIPK1 family member did not bind DCAF7. Immunoprecipitation and pulldown experiments identified DCAF7 as an adaptor for the association of the adenovirus E1A protein with DYRK1A and HIPK2. Furthermore, DCAF7 was required for the hyperphosphorylation of E1A in DYRK1A or HIPK2 overexpressing cells. Our results characterize DCAF7 as a substrate recruiting subunit of DYRK1A and HIPK2 and suggest that it is required for the negative effect of DYRK1A on E1A-induced oncogenic transformation.

10 July 2014 in Epigenetics
Verified
Journal Article
Closed access
VKVera Kloten
Vera Kloten
MRMichael Rose
Michael Rose
SKSophie Kaspar
Sophie Kaspar
SSSaskia von Stillfried
Saskia von Stillfried
RKRuth Knüchel
Ruth Knüchel
Edgar DahlEdgar Dahl
Edgar Dahl
Inter-α-trypsin inhibitor heavy chain 5 (ITIH5) is supposed to be involved in extracellular matrix stability and thus may play a key role in the inhibition of tumor progression. The current study i...

12 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
WDWallid Deb
Wallid Deb
TBThomas Besnard
Thomas Besnard
FDFlorence Desprez
Florence Desprez
BCBenjamin Cogné
Benjamin Cogné
LFLaura Do Souto Ferreira
Laura Do Souto Ferreira
SKSébastien Küry
Sébastien Küry
Poly(rC)-binding protein 1 (PCBP1), a splicing factor and key member of the hnRNP E family, was initially characterized for its tumor suppressive properties. More recently, its role in regulating gene expression in the brain and nervous system has attracted growing interest. Through an international multicenter collaboration, we identified 13 de novo pathogenic variants in PCBP1 across 13 unrelated families. All affected individuals exhibited intellectual disability (ID), with autism spectrum disorder (ASD) as a prominent feature. Functional analysis in primary hippocampal mouse neuron cultures demonstrated that PCBP1 variants impair dendritic arborization, underscoring their deleterious effects. Transcriptomic profiling by RNA sequencing of subjects-derived T cells showed a distinctive signature characterized by significantly increased exon skipping. These results highlight the essential role of PCBP1 in neurogenesis and neuritogenesis, revealing the impact of loss-of-function variants in cells harboring PCBP1 pathogenic variants, thereby confirming the link between splicing defects and neurodevelopmental disorders. Collectively, our findings demonstrate the critical role of PCBP1 in neurodevelopment, reaffirming the importance of splicing regulation in mammalian neurodevelopment.